Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 8/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201866 | 0.84 | MEN1 (0.70) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL30822583 | 0.84 | MEN1 (0.70) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL2197204 | 0.83 | MEN1 (0.68) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL27189439 | 0.82 | MEN1 (0.56) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL22717033 | 0.82 | NR4A2 (0.70) | MEN1KMT2ANR4A2MAOBSMPD1 | |
| SCHEMBL2197201 | 0.81 | PTGER1 (0.59) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL20819388 | 0.80 | MEN1 (0.54) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL1202881 | 0.80 | SIRT2 (0.59) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL19251587 | 0.78 | SIRT2 (0.62) | MEN1KMT2AHTTGFERHSD17B10 | |
| SCHEMBL20103304 | 0.77 | CYP2C9 (0.57) | MEN1KMT2AHTTGFERHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | MEN1 4514/4885KMT2A 3114/4885HTT 3053/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | MEN1 4514/4885KMT2A 3114/4885HTT 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.